Govind Persad (also @govindpersad.bsky.social)

Despite the efficacy of GLP-1s in treating obesity, the high cost of these drugs pose significant challenges for public health systems worldwide. In @TheLancet, Johan Dellgren, @GovindPersad, and I look at the limitations and the promises of GLP-1s. thelancet.com/journals/lance…

Association of Race and Ethnicity With High Longevity Deceased Donor Kidney Transplantation Under the US Kidney Allocation System buff.ly/3QiZAF2 @PeterPReese1 @MildaSaundersMD @DrMonicaPeek @GovindPersad @WF_Parker @uofcneph

Govind Persad, JD, PhD, on Understanding the Legal and Ethical Challenges AI Poses in Oncology ascopost.com/issues/may-25-… #oncology #AI @GovindPersad

There are many more results in the paper, so check it out! tandfonline.com/doi/full/10.10… (Feel free to email/DM me if you can't access it.) And a huge shout out to the whole VIBES team: @sophiehgibert, Leila Orszag, @_Haley_Sullivan, Rachel Fei, @GovindPersad, and @emily_a_largent.

Our article, Bioethicists Today: Results of the Views in Bioethics Survey (VIBeS), is now out in AJOB! We surveyed 824 US bioethicists on: (1) Major issues in bioethics, like medical aid in dying, paying organ donors, abortion, and many others (2) Their backgrounds 🧵

With @ZekeEmanuel @matthew_s_mccoy & Johan Dellgren, drawing on work presented @BCEPShealth x.com/JessamyBagenal…

'Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists' is out in @NEJM (ungated) nejm.org/doi/full/10.10… We propose a framework to guide goverments, professional societies, & docs in allocation choices about drugs like semaglutide (#Ozempic/#Wegovy) when demand > supply

"Coverage for weight-loss drugs could reduce obesity immediately while less consumption of harmful foods could help prevent it. Fewer people would need expensive treatments like Wegovy in the longer term." @GovindPersad & @ZekeEmanuel via @WSJopinion wsj.com/articles/for-o…

In my latest for @WSJ, @GovindPersad & I argue that North Carolina’s decision to deny coverage for GLP-1 drugs like #ozempic for individuals with obesity is both unethical and short-sighted. Read below ⬇️ 1/4 #cxrecs_s" target="_blank" rel="nofollow noopener">wsj.com/articles/for-o…

For Obese Patients, Wegovy Is Worth the Cost by @GovindPersad and @ZekeEmanuel wsj.com/articles/for-o… via @WSJopinion

Here is another link if you have trouble accessing the op-ed wsj.com/articles/for-o…

Last, while trade-offs in drug spending are inevitable, creative use of Pigouvian taxes could lessen their sharpness Taxing soda & other obesogenic foods could raise revenues for covering GLP-1 receptor agonists, while mitigating the need for them. npr.org/sections/healt…

North Carolina & other health systems are being unethical when they categorically refuse to cover GLP-1 receptor agonists (e.g. Ozempic, Mounjaro) for obesity. So I & @ZekeEmanuel argue in our @WSJ op-ed. wsj.com/articles/for-o… Thread highlighting a few points 1/5 #bioethics

@CourtneyGJoslin @michlawreview Thank you!

@GovindPersad @michlawreview So important! Looking forward to reading.

Revised draft of “Antiracist Medicine in Colorblind Courts,” forthcoming @michlawreview: papers.ssrn.com/sol3/papers.cf… Added material on new §1981, §1557, and Equal Protection litigation against health & other programs that consider individuals’ race. New TX & UT laws also discussed

Some of the grant cases are patterned on litigation against non-health grantmakers (e.g. Atlanta's Fearless Fund) being brought by the same organization and attorneys that litigated the Harvard/UNC affirmative action cases: reuters.com/sustainability…

Litigation has targeted consideration of individuals’ race in: -grants to health trainees reuters.com/legal/governme…; ualrpublicradio.org/local-regional… -physician recruitment litigationtracker.law.georgetown.edu/litigation/do-… -medical board composition litigationtracker.law.georgetown.edu/litigation/do-…; apnews.com/article/lawsui…